Reaction Biology, a drug discovery and development services provider, completed the acquisition of Bioassay, a biotechnology company. Financial terms were not disclosed. "Market demand is increasing globally for large molecule services as biopharmaceutical companies search for new treatment options for patients suffering with cancer and other serious diseases. This transaction enables Reaction Biology to add Bioassay GmbH's impressive clinical phase and post-approval infrastructure, which includes large molecule capabilities, as well as its GMP and GLP accreditations, to our expanding suite of drug discovery and development services. We can now provide our customers with even broader offerings to meet their research and development goals," John H. Johnson, Reaction Biology CEO.